Get the Stockscreener App
228.54
0.34%
-0.94
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $228.54, with a volume of 3.19M.
It is down -0.34% in the last 24 hours and up +4.30% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$229.48
Open:
$229
24h Volume:
3.19M
Relative Volume:
0.50
Market Cap:
$403.98B
Revenue:
$61.16B
Net Income/Loss:
$4.19B
P/E Ratio:
96.78
EPS:
2.3614
Net Cash Flow:
$17.82B
1W Performance:
-1.79%
1M Performance:
+4.30%
6M Performance:
+8.59%
1Y Performance:
+12.06%
1-Day Range:
$227.67
$230.76
1-Week Range:
$223.02
$234.00
52-Week Range:
$164.39
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
228.57 | 405.58B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
LLY
Lilly Eli Co
|
1,043.49 | 998.60B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
246.04 | 592.45B | 94.19B | 26.80B | 19.70B | 11.05 |
|
AZN
Astrazeneca Plc
|
207.00 | 317.72B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
166.99 | 314.27B | 54.72B | 14.02B | 15.32B | 7.1855 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
How Pipeline Shifts And Competition Are Reshaping The AbbVie (ABBV) Investment Narrative - Yahoo Finance
AbbVie makes $380 million ‘made in the U.S.’ move - thestreet.com
Governor Pritzker Announces Major AbbVie Manufacturing Expansion - RiverBender.com
AbbVie to spend $380M on two new manufacturing facilities in Illinois - Manufacturing Dive
Is AbbVie Stock Underperforming the Dow? - Barchart.com
AbbVie Plans to Launch Offering of Senior Notes - marketscreener.com
AbbVie to Present at the TD Cowen 46th Annual Health Care Conference - Investing News Network
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
This High‑Yield Pharma Beast AbbVie Could Turn Dividends Into Life‑Changing Income - Nasdaq
AbbVie announces $380m investment in North Chicago API facilities - Pharmaceutical Technology
FDA Approves AbbVie (ABBV) VENCLEXTA and Acalabrutinib Combination for First-Line CLL - Yahoo! Finance Canada
North Chicago-based AbbVie investing $380 million on new pharmaceutical plants - Chicago Sun-Times
AbbVie (ABBV) to Invest $380M in New Pharmaceutical Plants - GuruFocus
AbbVie to invest $380 million to expand US manufacturing in Illinois - 1470 & 100.3 WMBD
AbbVie reveals blueprints for two new manufacturing sites in Chicago - FirstWord Pharma
AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States - Investing News Network
AbbVie to build 2 more manufacturing facilities in North Chicago with $380M investment - The Business Journals
AbbVie plans to spend $380 million building two new manufacuturing facilities in North Chicago - Yahoo Finance
'Forefront of innovation': State announces major $380M expansion at AbbVie in Lake County, creating 300 new jobs - Lake and McHenry County Scanner
Barclays Initiates AbbVie (ABBV) with Overweight Rating on Growth Potential - Finviz
AbbVie plans $380 million manufacturing expansion in North Chicago - StreetInsider
AbbVie to build 2 new manufacturing facilities at North Chicago headquarters, company and Gov. Pritzker announce - WGN-TV
AbbVie plans $380M manufacturing expansion in Illinois - Investing.com
AbbVie (ABBV) Invests $380M in New Manufacturing Facilities - GuruFocus
AbbVie to Invest $380 Million in Chicago to Further Expand US API Manufacturing - CHEManager
AbbVie to Invest $380 Million in 2 New Facilities in Illinois - marketscreener.com
AbbVie to Invest $380 Million to Construct 2 Active Pharmaceutical Ingredient Production Sites in Chicago - marketscreener.com
AbbVie to invest $380M in two API manufacturing facilities at Illinois campus - TipRanks
AbbVie announces $380 million investments in North Chicago - marketscreener.com
Abbvie Announces $380 Million Investments In North Chicago - TradingView
AbbVie investing $380M on two new plants in North Chicago, adding 300 employees - Crain's Chicago Business
AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States – Company AnnouncementFT.com - Financial Times
Students - AbbVie
UK's NICE Recommends AbbVie's Follicular Lymphoma Drug - marketscreener.com
Johnson & Johnson vs. AbbVie: A Growth Showdown Amid Patent Cliffs - The Globe and Mail
Theodora Ross Joins Ideaya, Leaving Impact on AbbVie (ABBV) - GuruFocus
AbbVie Expands IPF Pipeline With New Phase 2a Study of ABBV-142 - The Globe and Mail
Heartland Bank & Trust Co Has $3.85 Million Position in AbbVie Inc. $ABBV - MarketBeat
Siligmueller & Norvid Wealth Advisors LLC Purchases Shares of 12,436 AbbVie Inc. $ABBV - MarketBeat
AbbVie (NYSE:ABBV) Upgraded to Strong-Buy at Barclays - MarketBeat
Fiera Capital Corp Has $38.12 Million Stake in AbbVie Inc. $ABBV - MarketBeat
New Graduates & Entry-Level positions - AbbVie
ABBV Stock Quote Price and Forecast - CNN
Beyond the Balance Sheet: What SWOT Reveals About AbbVie Inc (AB - GuruFocus
Evercore notes AbbVie Inc.’s (ABBV) Tremfya gains market share, but future earnings growth may be limited - MSN
Students & New Graduates - AbbVie
AbbVie Inc. SEC 10-K Report - TradingView
AbbVie wins FDA nod for leukemia therapy (update) (ABBV:NYSE) - Seeking Alpha
Woodley Farra Manion Portfolio Management Inc. Buys 11,527 Shares of AbbVie Inc. $ABBV - MarketBeat
Barclays Initiates Coverage on ABBV with Overweight Rating | ABB - GuruFocus
Barclays Initiates Coverage of AbbVie (ABBV) with Overweight Recommendation - Nasdaq
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):